Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for potential securities fraud. This follows Regeneron's Q3 2024 financial results, which reported a 3% increase in U.S. net sales for EYLEA HD® and EYLEA®.
December 06, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities fraud, following a 3% increase in U.S. net sales for EYLEA products in Q3 2024.
The investigation into potential securities fraud could negatively impact investor confidence and lead to short-term stock price volatility. Despite positive sales growth, legal issues often overshadow financial performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100